Promore Pharma AB - ESG Rating & Company Profile powered by AI
This page includes a questions and answers table for Promore Pharma AB. The ESG score covers seventeen United Nations SDGs including: 'Affordable & Clean Energy', 'Climate Action' and 'Peace, Justice & Strong Institutions'. Jump to the end of this page for potential risks for Promore Pharma AB based on sector, geography and marketcap.
Promore Pharma AB in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.8; made up of an environmental score of 2.7, social score of 6.4 and governance score of 5.3.
4.8
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 1082 | Respiratorius AB (publ) | 4.9 | High |
| 1082 | Shenzhen Chipscreen Biosciences Co Ltd | 4.9 | High |
| 1121 | Promore Pharma AB | 4.8 | High |
| 1121 | Heat Biologics Inc | 4.8 | High |
| 1121 | Curis Inc | 4.8 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Promore Pharma AB have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Promore Pharma AB disclose current and historical energy intensity?
Sign up for free to unlockDoes Promore Pharma AB report the average age of the workforce?
Sign up for free to unlockDoes Promore Pharma AB reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Promore Pharma AB disclose its ethnicity pay gap?
Sign up for free to unlockDoes Promore Pharma AB disclose cybersecurity risks?
Sign up for free to unlockDoes Promore Pharma AB offer flexible work?
Sign up for free to unlockDoes Promore Pharma AB have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Promore Pharma AB disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Promore Pharma AB conduct supply chain audits?
Sign up for free to unlockDoes Promore Pharma AB disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Promore Pharma AB conduct 360 degree staff reviews?
Sign up for free to unlockDoes Promore Pharma AB disclose the individual responsible for D&I?
Sign up for free to unlockDoes Promore Pharma AB disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Promore Pharma AB disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Promore Pharma AB disclose water use targets?
Sign up for free to unlockDoes Promore Pharma AB have careers partnerships with academic institutions?
Sign up for free to unlockDid Promore Pharma AB have a product recall in the last two years?
Sign up for free to unlockDoes Promore Pharma AB disclose incidents of discrimination?
Sign up for free to unlockDoes Promore Pharma AB allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Promore Pharma AB issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Promore Pharma AB disclose parental leave metrics?
Sign up for free to unlockDoes Promore Pharma AB disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Promore Pharma AB disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Promore Pharma AB disclose the pay ratio of women to men?
Sign up for free to unlockDoes Promore Pharma AB support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Promore Pharma AB disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Promore Pharma AB reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Promore Pharma AB involved in embryonic stem cell research?
Sign up for free to unlockDoes Promore Pharma AB disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Promore Pharma AB disclose its waste policy?
Sign up for free to unlockDoes Promore Pharma AB report according to TCFD requirements?
Sign up for free to unlockDoes Promore Pharma AB disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Promore Pharma AB disclose energy use targets?
Sign up for free to unlockDoes Promore Pharma AB disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Promore Pharma AB have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Promore Pharma AB
These potential risks are based on the size, segment and geographies of the company.
Promore Pharma AB (publ), a biopharmaceutical company, develops peptide-based drug candidates in Sweden and internationally. Its product candidates include PXL01 that is in Phase IIa study for the prevention of post-surgical adhesions and scars, and for the prevention of dermal scars, as well as for tendon repair surgery in the hand; and LL-37, which is in Phase IIb clinical studies for treating patients with venous leg ulcers, stimulate the healing of chronic wounds, and for the treatment of diabetic foot ulcers. It entered into a cooperation agreement with Fidia Farmaceutici S.p.A. for the production of hyaluronic acid syringes. The company was formerly known as Lipopeptide AB and changed its name to Promore Pharma AB (publ) in January 2017. Promore Pharma AB (publ) was founded in 2002 and is headquartered in Solna, Sweden.